{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:05:30Z","timestamp":1782486330520,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.amjcard.2023.01.035","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T22:44:56Z","timestamp":1676155496000},"page":"116-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Perspective on Antiarrhythmic Drug Combinations"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5505-1866","authenticated-orcid":false,"given":"James A.","family":"Reiffel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Kowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.amjcard.2023.01.035_bib0001","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1097\/00005344-199220002-00012","article-title":"Drug combinations and interactions with class III agents","volume":"20","author":"Marcus","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"suppl 6","key":"10.1016\/j.amjcard.2023.01.035_bib0002","first-page":"S48","article-title":"Combination of antiarrhythmic drugs","volume":"17","author":"L\u00fcderitz","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0003","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2165\/00003495-198500294-00014","article-title":"Logic and empiricism in the selection of antiarrhythmic agents. The role of drug combinations","volume":"29","author":"Coumel","year":"1985","journal-title":"Drugs"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0005","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0006","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0195-668X(03)00311-7","article-title":"Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study)","volume":"24","author":"De Simone","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0007","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ehj.2004.04.015","article-title":"Prevention of Atrial Fibrillation after Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial","volume":"25","author":"Fetsch","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0008","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2022.03.016","article-title":"Atrial fibrillation: is rhythm control required, and if so, how, and what is the internist's role?","volume":"135","author":"Reiffel","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1026288508343","article-title":"Rationale and patient selection for \u2018hybrid\u2019 drug and device therapy in atrial and ventricular arrhythmias","volume":"9","author":"Camm","year":"2003","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.repc.2017.11.018","article-title":"Dramatic reduction of ventricular tachycardia burden after dronedarone plus mexiletine treatment in a patient refractory to hybrid ablation","volume":"39","author":"Frutos-L\u00f3pez","year":"2020","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0011","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.19102\/icrm.2020.110404","article-title":"Reduced-dose antiarrhythmic drugs: valuable or valueless?","volume":"11","author":"Reiffel","year":"2020","journal-title":"J Innov Card Rhythm Manag"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1540-8159.1986.tb06613.x","article-title":"Combination antiarrhythmic drug therapy for ventricular tachyarrhythmias","volume":"9","author":"Greenspan","year":"1986","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0013","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","article-title":"Modernized classification of cardiac antiarrhythmic drugs","volume":"138","author":"Lei","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0014","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archinte.158.4.325","article-title":"Pharmacological effects of antiarrhythmic drugs. Review and update","volume":"158","author":"Kowey","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1067\/mhj.2000.106640","article-title":"Classification and pharmacology of antiarrhythmic drugs","volume":"140","author":"Kowey","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0016","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0002-8703(94)90552-5","article-title":"Usefulness of oral quinidine-mexiletine combination therapy for sustained ventricular tachyarrhythmias as assessed by programmed electrical stimulation when quinidine monotherapy has failed","volume":"127","author":"Bonavita","year":"1994","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0017","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00005344-199011000-00001","article-title":"Role of quinidine in the mexiletine-quinidine interaction: electrophysiologic correlates of enhanced antiarrhythmic efficacy","volume":"16","author":"Duff","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0018","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/0735-1097(90)90255-N","article-title":"Low dose quinidine-mexiletine combination therapy versus quinidine monotherapy for treatment of ventricular arrhythmias","volume":"15","author":"Giardina","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0019","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/0002-8703(88)90482-6","article-title":"Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias","volume":"115","author":"Whitford","year":"1988","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00005344-198912000-00003","article-title":"Frequency-dependent effect of quinidine, mexiletine, and their combination on postrepolarization refractoriness in vivo","volume":"14","author":"Costard-Jaeckle","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jacep.2015.05.008","article-title":"Mexiletine prevents recurrent torsades de pointes in acquired long QT syndrome refractory to conventional measures","volume":"1","author":"Badri","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0022","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","volume":"55","author":"Drew","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0023","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1592\/phco.27.9.1297","article-title":"Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes","volume":"27","author":"Shah","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0024","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0025","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0735-1097(10)80153-6","article-title":"Role of combination drug therapy with a class IC antiarrhythmic agent and mexiletine for ventricular tachycardia","volume":"17","author":"Mendes","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0026","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/107424849600100409","article-title":"Controlling paroxysmal atrial fibrillation by a combination of amiodarone and flecainide: description of a case with 15-year follow-up","volume":"1","author":"Altamirano","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0027","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.ijcard.2013.04.154","article-title":"Amiodarone plus flecainide combination therapy in patients with amiodarone refractory paroxysmal atrial fibrillation","volume":"168","author":"Kagal","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0028","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCEP.115.002856","article-title":"The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism","volume":"8","author":"Reiffel","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0029","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0735-1097(96)00423-8","article-title":"Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence","volume":"29","author":"Lee","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0030","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/01.CIR.66.6.1205","article-title":"Antiarrhythmic drug combinations in the treatment of ventricular tachycardia","volume":"66","author":"Dl","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.CIR.84.1.101","article-title":"A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia","volume":"84","author":"Toivonen","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0032","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/01.CIR.74.5.1037","article-title":"Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia","volume":"74","author":"Marchlinski","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0033","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.hrthm.2016.12.010","article-title":"Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy","volume":"14","author":"Ermakov","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0034","first-page":"278","article-title":"Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy","volume":"24","author":"Rolland","year":"2022","journal-title":"Europace"},{"issue":"suppl","key":"10.1016\/j.amjcard.2023.01.035_bib0035","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.1177\/1074248410371947","article-title":"Atrial fibrillation-the final frontier","volume":"15","author":"Govindan","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"suppl","key":"10.1016\/j.amjcard.2023.01.035_bib0036","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1177\/1074248410377617","article-title":"Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations","volume":"15","author":"Singh","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0037","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ccep.2016.02.011","article-title":"Ranolazine: electrophysiologic effect, efficacy, and safety in patients with cardiac arrhythmias","volume":"8","author":"Shenasa","year":"2016","journal-title":"Card Electrophysiol Clin"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0038","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2012.04.044","article-title":"Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation","volume":"110","author":"Fragakis","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0039","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0003319713477911","article-title":"Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery","volume":"65","author":"Simopoulos","year":"2014","journal-title":"Angiology"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jacc.2010.08.600","article-title":"Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation","volume":"56","author":"Burashnikov","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0041","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0002-8703(93)90109-M","article-title":"The effectiveness and safety of the simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation","volume":"125","author":"Kerin","year":"1993","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0042","first-page":"477","article-title":"Treatment of atrial fibrillation of recent onset by a combination of quinidine and amiodarone","volume":"100","author":"Allaria","year":"1982","journal-title":"Clin Ter"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0043","first-page":"390","article-title":"Controlled study of the quinidine-amiodarone combination in the reversal of auricular fibrillation","volume":"41","author":"De Posada","year":"1988","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0044","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjcard.2010.02.016","article-title":"Effect of restoration of sinus rhythm by extensive antiarrhythmic drugs in predicting results of catheter ablation of persistent atrial fibrillation","volume":"106","author":"Igarashi","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.hrthm.2012.09.015","article-title":"Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia","volume":"10","author":"Verrier","year":"2013","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0046","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00002018-200023060-00003","article-title":"Antiarrhythmic agents: drug interactions of clinical significance","volume":"23","author":"Trujillo","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0047","article-title":"Gopinathannair R, from the American Heart Association Electrocardiography and Arrhythmias Committee of the Council of Clinical Cardiology. Drug interactions affecting antiarrhythmic drug use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.amjcard.2023.01.035_bib0048","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.1984.tb14507.x","article-title":"Clinical consequences of the lipophilicity and plasma protein binding of antiarrhythmic drugs and active metabolites in man","volume":"432","author":"Drayer","year":"1984","journal-title":"Ann N Y Acad Sci"},{"issue":"suppl","key":"10.1016\/j.amjcard.2023.01.035_bib0049","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1177\/106002808902300706","article-title":"Protein binding: what does it mean?","volume":"23","author":"Scheife","year":"1989","journal-title":"DICP"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:45:50Z","timestamp":1757573150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":49,"alternative-id":["S0002914923000346"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.01.035","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspective on Antiarrhythmic Drug Combinations","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}